Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer [Yahoo! Finance]
ONO PHARM CO UNSP/ADR (OPHLY)
NASDAQ:AMEX Investor Relations:
ono.co.jp/eng/investor/index.html
Company Research
Source: Yahoo! Finance
Numab to receive upfront payment and eligible to receive additional milestone payments plus option to co-develop with profit split arrangement in the United States Agreement marks third collaboration agreement between Numab and Ono Pharmaceutical HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab's proprietary discovery and engineering technology platform. Under the terms of the agreement, Ono has obtained an option to in-license NM49 from Numab for global development and commercialization, with Numab retaining an option to co-develop and commercialize in the United States. The option can be exercised prior to the start of a Phase 3 clinical trial and, if exercised, N
Show less
Read more
Impact Snapshot
Event Time:
OPHLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPHLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPHLY alerts
High impacting ONO PHARM CO UNSP/ADR news events
Weekly update
A roundup of the hottest topics
OPHLY
News
- XCOPRI® (cenobamate tablets) CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube [Yahoo! Finance]Yahoo! Finance
- SK Life Science Announces Data Presentations for XCOPRI® (cenobamate tablets) CV at the 2024 American Academy of Neurology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL [Yahoo! Finance]Yahoo! Finance
- Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders [Yahoo! Finance]Yahoo! Finance
- ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University [Yahoo! Finance]Yahoo! Finance